Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Inventory: 2020-2024

Historic Inventory for Maravai Lifesciences Holdings (MRVI) over the last 5 years, with Dec 2024 value amounting to $50.1 million.

  • Maravai Lifesciences Holdings' Inventory fell 10.31% to $45.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.3 million, marking a year-over-year decrease of 10.31%. This contributed to the annual value of $50.1 million for FY2024, which is 2.56% down from last year.
  • According to the latest figures from FY2024, Maravai Lifesciences Holdings' Inventory is $50.1 million, which was down 2.56% from $51.4 million recorded in FY2023.
  • In the past 5 years, Maravai Lifesciences Holdings' Inventory registered a high of $51.6 million during FY2021, and its lowest value of $33.3 million during FY2020.
  • Over the past 3 years, Maravai Lifesciences Holdings' median Inventory value was $50.1 million (recorded in 2024), while the average stood at $48.2 million.
  • In the last 5 years, Maravai Lifesciences Holdings' Inventory skyrocketed by 54.82% in 2021 and then fell by 16.30% in 2022.
  • Maravai Lifesciences Holdings' Inventory (Yearly) stood at $33.3 million in 2020, then spiked by 54.82% to $51.6 million in 2021, then decreased by 16.30% to $43.2 million in 2022, then rose by 19.11% to $51.4 million in 2023, then fell by 2.56% to $50.1 million in 2024.